FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.
What happened
FDA inspected Senthil Specialty Hospital in Pondicherry, Puducherry, India, from January 20 to 24, 2025, as part of its Bioresearch Monitoring Program. FDA found that the clinical investigator did not follow the investigational plan for a clinical in vivo bioequivalence study. For certain subjects, required hematology and pulmonary function safety assessments were not completed after dosing on Day 8, Day 22, and Day 35 in both Period I and Period II.
What FDA found
The investigator failed to ensure the study was conducted according to the investigational plan because required hematology and pulmonary function safety assessments were not completed at protocol-specified times.
21 CFR 312.60
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations in the future, and include reasoning and supporting information if you believe you complied.
Who should pay attention
- clinical research sites conducting FDA-regulated bioequivalence studies
- sponsors relying on investigator-site safety data
- ethics committees overseeing clinical trials
This is a summary. Read the original letter on fda.gov.